LANXESS（1LXS）株式概要ランクセス・アクチェンゲゼルシャフトは、その子会社とともに、化学中間体、添加剤、特殊化学品、消費者保護製品の開発、製造、マーケティングを世界中で行う特殊化学品会社として事業を展開しています。 詳細1LXS ファンダメンタル分析スノーフレーク・スコア評価5/6将来の成長0/6過去の実績0/6財務の健全性3/6配当金0/6報酬当社が推定した公正価値より62.5%で取引されている 同業他社や業界と比較して、良好な取引価格 リスク分析Italian市場と比較して、過去 3 か月間の株価の変動が非常に大きい負債は営業キャッシュフローで十分にカバーされていない すべてのリスクチェックを見る1LXS Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€16.9383.5% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-951m8b2016201920222025202620282031Revenue €6.4bEarnings €602.9mAdvancedSet Fair ValueView all narrativesLANXESS Aktiengesellschaft 競合他社Cementir HoldingSymbol: BIT:CEMMarket cap: €2.1bCaltagironeSymbol: BIT:CALTMarket cap: €1.1bSOLSymbol: BIT:SOLMarket cap: €5.2bZignago VetroSymbol: BIT:ZVMarket cap: €625.8m価格と性能株価の高値、安値、推移の概要LANXESS過去の株価現在の株価€16.9352週高値€27.7052週安値€11.85ベータ1.161ヶ月の変化-7.79%3ヶ月変化-13.97%1年変化-35.63%3年間の変化-52.93%5年間の変化-72.18%IPOからの変化-71.81%最新ニュースUpcoming Dividend • May 15Upcoming dividend of €0.10 per shareEligible shareholders must have bought the stock before 22 May 2026. Payment date: 27 May 2026. The company is not currently making a profit but it is cash flow positive. Trailing yield: 0.5%. Lower than top quartile of Italian dividend payers (4.4%). Lower than average of industry peers (3.3%).Reported Earnings • May 07First quarter 2026 earnings released: €1.63 loss per share (vs €0.66 loss in 1Q 2025)First quarter 2026 results: €1.63 loss per share (further deteriorated from €0.66 loss in 1Q 2025). Revenue: €1.38b (down 14% from 1Q 2025). Net loss: €141.0m (loss widened 147% from 1Q 2025). Revenue is forecast to grow 3.7% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has fallen by 21% per year, which means it is performing significantly worse than earnings.Declared Dividend • Apr 13Dividend of €0.10 announcedDividend of €0.10 is the same as last year. Ex-date: 22nd May 2026 Payment date: 27th May 2026 Dividend yield will be 0.5%, which is lower than the industry average of 2.8%.お知らせ • Apr 12LANXESS Aktiengesellschaft announces Annual dividend, payable on May 27, 2026LANXESS Aktiengesellschaft announced Annual dividend of EUR 0.1000 per share payable on May 27, 2026, ex-date on May 22, 2026 and record date on May 25, 2026.お知らせ • Apr 10LANXESS Aktiengesellschaft, Annual General Meeting, May 21, 2026LANXESS Aktiengesellschaft, Annual General Meeting, May 21, 2026, at 10:00 W. Europe Standard Time.Reported Earnings • Mar 19Full year 2025 earnings released: €6.68 loss per share (vs €2.05 loss in FY 2024)Full year 2025 results: €6.68 loss per share (further deteriorated from €2.05 loss in FY 2024). Revenue: €5.67b (down 11% from FY 2024). Net loss: €577.0m (loss widened 226% from FY 2024). Revenue is forecast to grow 2.4% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Chemicals industry in Italy. Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has fallen by 32% per year, which means it is performing significantly worse than earnings.最新情報をもっと見るRecent updatesUpcoming Dividend • May 15Upcoming dividend of €0.10 per shareEligible shareholders must have bought the stock before 22 May 2026. Payment date: 27 May 2026. The company is not currently making a profit but it is cash flow positive. Trailing yield: 0.5%. Lower than top quartile of Italian dividend payers (4.4%). Lower than average of industry peers (3.3%).Reported Earnings • May 07First quarter 2026 earnings released: €1.63 loss per share (vs €0.66 loss in 1Q 2025)First quarter 2026 results: €1.63 loss per share (further deteriorated from €0.66 loss in 1Q 2025). Revenue: €1.38b (down 14% from 1Q 2025). Net loss: €141.0m (loss widened 147% from 1Q 2025). Revenue is forecast to grow 3.7% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has fallen by 21% per year, which means it is performing significantly worse than earnings.Declared Dividend • Apr 13Dividend of €0.10 announcedDividend of €0.10 is the same as last year. Ex-date: 22nd May 2026 Payment date: 27th May 2026 Dividend yield will be 0.5%, which is lower than the industry average of 2.8%.お知らせ • Apr 12LANXESS Aktiengesellschaft announces Annual dividend, payable on May 27, 2026LANXESS Aktiengesellschaft announced Annual dividend of EUR 0.1000 per share payable on May 27, 2026, ex-date on May 22, 2026 and record date on May 25, 2026.お知らせ • Apr 10LANXESS Aktiengesellschaft, Annual General Meeting, May 21, 2026LANXESS Aktiengesellschaft, Annual General Meeting, May 21, 2026, at 10:00 W. Europe Standard Time.Reported Earnings • Mar 19Full year 2025 earnings released: €6.68 loss per share (vs €2.05 loss in FY 2024)Full year 2025 results: €6.68 loss per share (further deteriorated from €2.05 loss in FY 2024). Revenue: €5.67b (down 11% from FY 2024). Net loss: €577.0m (loss widened 226% from FY 2024). Revenue is forecast to grow 2.4% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Chemicals industry in Italy. Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has fallen by 32% per year, which means it is performing significantly worse than earnings.New Risk • Mar 08New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Italian stocks, typically moving 8.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (17% operating cash flow to total debt). Share price has been highly volatile over the past 3 months (8.4% average weekly change).Buy Or Sell Opportunity • Jan 21Now 24% overvaluedOver the last 90 days, the stock has fallen 18% to €17.42. The fair value is estimated to be €14.01, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 11% over the last 3 years. Meanwhile, the company became loss making. For the next 3 years, revenue is forecast to grow by 1.6% per annum. Earnings are also forecast to grow by 56% per annum over the same time period.Buy Or Sell Opportunity • Dec 29Now 22% overvaluedOver the last 90 days, the stock has fallen 17% to €17.57. The fair value is estimated to be €14.36, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 11% over the last 3 years. Meanwhile, the company became loss making. For the next 3 years, revenue is forecast to grow by 1.5% per annum. Earnings are also forecast to grow by 39% per annum over the same time period.Buy Or Sell Opportunity • Nov 27Now 22% overvaluedOver the last 90 days, the stock has fallen 29% to €17.30. The fair value is estimated to be €14.12, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 11% over the last 3 years. Meanwhile, the company became loss making. For the next 3 years, revenue is forecast to grow by 1.6% per annum. Earnings are also forecast to grow by 45% per annum over the same time period.Reported Earnings • Nov 08Third quarter 2025 earnings released: €0.89 loss per share (vs €0.012 profit in 3Q 2024)Third quarter 2025 results: €0.89 loss per share (down from €0.012 profit in 3Q 2024). Revenue: €1.34b (down 16% from 3Q 2024). Net loss: €77.0m (down €78.0m from profit in 3Q 2024). Revenue is forecast to grow 2.0% p.a. on average during the next 3 years, compared to a 7.7% growth forecast for the Chemicals industry in Italy. Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has only fallen by 24% per year, which means it has not declined as severely as earnings.New Risk • Nov 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 5.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (18% operating cash flow to total debt). Minor Risk Share price has been volatile over the past 3 months (5.9% average weekly change).Buy Or Sell Opportunity • Nov 04Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 19% to €19.39. The fair value is estimated to be €24.29, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 9.2% over the last 3 years. Meanwhile, the company became loss making. For the next 3 years, revenue is forecast to grow by 1.0% per annum. Earnings are also forecast to grow by 64% per annum over the same time period.お知らせ • Oct 07+ 3 more updatesLANXESS Aktiengesellschaft to Report Q3, 2026 Results on Nov 05, 2026LANXESS Aktiengesellschaft announced that they will report Q3, 2026 results at 7:00 AM, Central European Standard Time on Nov 05, 2026New Risk • Sep 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 5.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (18% operating cash flow to total debt). Minor Risk Share price has been volatile over the past 3 months (5.4% average weekly change).Reported Earnings • Aug 14Second quarter 2025 earnings released: €0.52 loss per share (vs €0.18 loss in 2Q 2024)Second quarter 2025 results: €0.52 loss per share (further deteriorated from €0.18 loss in 2Q 2024). Revenue: €1.47b (down 13% from 2Q 2024). Net loss: €45.0m (loss widened 181% from 2Q 2024). Revenue is forecast to grow 2.4% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Chemicals industry in Italy. Over the last 3 years on average, earnings per share has fallen by 57% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings.New Risk • Aug 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 5.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.4x net interest cover). Minor Risk Share price has been volatile over the past 3 months (5.4% average weekly change).New Risk • Jul 04New major risk - Revenue and earnings growthEarnings have declined by 69% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.4x net interest cover). Earnings have declined by 69% per year over the past 5 years.Upcoming Dividend • May 16Upcoming dividend of €0.10 per shareEligible shareholders must have bought the stock before 23 May 2025. Payment date: 27 May 2025. The company is not currently making a profit but it is cash flow positive. Trailing yield: 0.4%. Lower than top quartile of Italian dividend payers (5.4%). Lower than average of industry peers (2.6%).Reported Earnings • May 10First quarter 2025 earnings released: €0.66 loss per share (vs €1.14 loss in 1Q 2024)First quarter 2025 results: €0.66 loss per share (improved from €1.14 loss in 1Q 2024). Revenue: €1.60b (flat on 1Q 2024). Net loss: €57.0m (loss narrowed 42% from 1Q 2024). Revenue is forecast to grow 2.0% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Chemicals industry in Italy. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 68 percentage points per year, which is a significant difference in performance.お知らせ • Apr 11LANXESS Aktiengesellschaft, Annual General Meeting, May 22, 2025LANXESS Aktiengesellschaft, Annual General Meeting, May 22, 2025, at 10:00 W. Europe Standard Time.お知らせ • Apr 02UBE Corporation (TSE:4208) completed the acquisition of Urethane Systems Business of LANXESS Aktiengesellschaft (XTRA:LXS) for approximately €500 million.UBE Corporation (TSE:4208) signed a contract to acquire Urethane Systems Business of LANXESS Aktiengesellschaft (XTRA:LXS) for an enterprise value of €460 million on October 3, 2024. For the last twelve months period ending September 30, 2024, Urethane Systems Business of LANXESS reported total revenue of €265 million and EBITDA of €50 million. The acquisition price is expected to be confirmed based on the price adjustment indicated in the stock purchase agreement. The acquisition will be financed through cash on hand and interest-bearing debt. The Urethane Systems business comprises 5 manufacturing sites globally as well as application laboratories in the USA, Europe and China. UBE Corporation will take over all operations from LANXESS with a total of around 400 employees. LANXESS will use the proceeds to reduce its net debt. The transaction is subject to the approval of the relevant authorities including regulatory approval. The transaction is expected to close in the first half of 2025. Nomura Holding America, Inc. acted as financial advisor to UBE Corporation. Matthias Töke, Katharina Spenner LL.M., Joachim Fröhlich LL.M., Katharina Weiner, Daniel Bork, Christoph Becker, Ariane Schaaf, Simone (Bach) Rieken LL.M., Johannes M. Baumann, LL.M., Christian Atzler, Christian Vocke, Richard Raoul Stefanink, Patrick H. Wilkening, Markus Hecht, Christian Reichel and Nicolas Kredel LL.M. of Baker & Mckenzie Partnerschaft Von Rechtsanwälten Wirtschaftsprüfern,Steuerberatern Und Solicitors acted as legal advisor to UBE Corporation. Masahiro Inaba, Byron Frost and Tetsuo Tsujimoto of Baker & McKenzie (Gaikokuho Joint Enterprise) acted as legal advisor to UBE Corporation. UBE Corporation (TSE:4208) completed the acquisition of Urethane Systems Business of LANXESS Aktiengesellschaft (XTRA:LXS) for approximately €500 million on April 1, 2025. All relevant antitrust authorities had granted the necessary approvals for the transactionお知らせ • Oct 04UBE Corporation (TSE:4208) signed a contract to acquire Urethane Systems Business of LANXESS Aktiengesellschaft (XTRA:LXS) for an enterprise value of €460 million.UBE Corporation (TSE:4208) signed a contract to acquire Urethane Systems Business of LANXESS Aktiengesellschaft (XTRA:LXS) for an enterprise value of €460 million on October 3, 2024. For the last twelve months period ending September 30, 2024, Urethane Systems Business of LANXESS reported total revenue of €265 million and EBITDA of €50 million. The acquisition price is expected to be confirmed based on the price adjustment indicated in the stock purchase agreement. The acquisition will be financed through cash on hand and interest-bearing debt. The Urethane Systems business comprises 5 manufacturing sites globally as well as application laboratories in the USA, Europe and China. UBE Corporation will take over all operations from LANXESS with a total of around 400 employees. LANXESS will use the proceeds to reduce its net debt. The transaction is subject to the approval of the relevant authorities including regulatory approval. The transaction is expected to close in the first half of 2025.株主還元1LXSIT ChemicalsIT 市場7D-4.6%-3.3%-0.3%1Y-35.6%28.9%16.8%株主還元を見る業界別リターン: 1LXS過去 1 年間で29.1 % の収益を上げたItalian Chemicals業界を下回りました。リターン対市場: 1LXSは、過去 1 年間で15.3 % のリターンを上げたItalian市場を下回りました。価格変動Is 1LXS's price volatile compared to industry and market?1LXS volatility1LXS Average Weekly Movement12.1%Chemicals Industry Average Movement5.3%Market Average Movement5.2%10% most volatile stocks in IT Market8.4%10% least volatile stocks in IT Market3.1%安定した株価: 1LXSの株価は、 Italian市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 1LXSの weekly volatility ( 12% ) は過去 1 年間安定していますが、依然としてItalianの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト186311,630Matthias Zachertlanxess.comランクセス・アクチェンゲゼルシャフト（LANXESS Aktiengesellschaft）は、子会社とともに、化学中間体、添加剤、特殊化学品、消費者保護製品の開発、製造、マーケティングを世界中で行う特殊化学品会社として事業を展開しています。事業セグメントは3つ：消費者保護、特殊添加物、先端中間体。コンシューマー・プロテクション部門は、材料保護製品、殺菌・衛生・防腐剤ソリューション、香料、水やその他の液体処理用の液体浄化技術、農薬・医薬品・特殊化学品業界向けの前駆体・中間体を提供している。特殊添加剤部門は、ゴム、プラスチック、塗料、電気・電子、建設業界向けの添加剤、潤滑剤、難燃剤、可塑剤、臭素誘導体を提供している。先端中間体部門は、基礎化学品、精密化学品、有機金属化合物、建材着色用無機顔料、塗料やコーティング剤を提供する。同部門は、農薬、自動車、建設、アロマ・香料、半導体・太陽電池、着色顔料などの業界に製品を供給しています。ランクセス・アクチェンゲゼルシャフトは1863年に設立され、ドイツのケルンに本社を置いています。もっと見るLANXESS Aktiengesellschaft 基礎のまとめLANXESS の収益と売上を時価総額と比較するとどうか。1LXS 基礎統計学時価総額€1.46b収益（TTM）-€661.00m売上高(TTM)€5.45b0.3xP/Sレシオ-2.2xPER（株価収益率1LXS は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計1LXS 損益計算書（TTM）収益€5.45b売上原価€4.38b売上総利益€1.07bその他の費用€1.73b収益-€661.00m直近の収益報告Mar 31, 2026次回決算日Aug 07, 2026一株当たり利益（EPS）-7.66グロス・マージン19.65%純利益率-12.13%有利子負債／自己資本比率71.7%1LXS の長期的なパフォーマンスは？過去の実績と比較を見る配当金0.6%現在の配当利回り-1%配当性向1LXS 配当は確実ですか？1LXS 配当履歴とベンチマークを見る1LXS 、いつまでに購入すれば配当金を受け取れますか？LANXESS 配当日配当落ち日May 22 2026配当支払日May 27 2026配当落ちまでの日数1 day配当支払日までの日数6 days1LXS 配当は確実ですか？1LXS 配当履歴とベンチマークを見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/20 05:41終値2026/05/20 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋LANXESS Aktiengesellschaft 15 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。35 アナリスト機関James KnightBarclaysAnil ShenoyBarclaysAndres Castanos-MollorBerenberg32 その他のアナリストを表示
Upcoming Dividend • May 15Upcoming dividend of €0.10 per shareEligible shareholders must have bought the stock before 22 May 2026. Payment date: 27 May 2026. The company is not currently making a profit but it is cash flow positive. Trailing yield: 0.5%. Lower than top quartile of Italian dividend payers (4.4%). Lower than average of industry peers (3.3%).
Reported Earnings • May 07First quarter 2026 earnings released: €1.63 loss per share (vs €0.66 loss in 1Q 2025)First quarter 2026 results: €1.63 loss per share (further deteriorated from €0.66 loss in 1Q 2025). Revenue: €1.38b (down 14% from 1Q 2025). Net loss: €141.0m (loss widened 147% from 1Q 2025). Revenue is forecast to grow 3.7% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has fallen by 21% per year, which means it is performing significantly worse than earnings.
Declared Dividend • Apr 13Dividend of €0.10 announcedDividend of €0.10 is the same as last year. Ex-date: 22nd May 2026 Payment date: 27th May 2026 Dividend yield will be 0.5%, which is lower than the industry average of 2.8%.
お知らせ • Apr 12LANXESS Aktiengesellschaft announces Annual dividend, payable on May 27, 2026LANXESS Aktiengesellschaft announced Annual dividend of EUR 0.1000 per share payable on May 27, 2026, ex-date on May 22, 2026 and record date on May 25, 2026.
お知らせ • Apr 10LANXESS Aktiengesellschaft, Annual General Meeting, May 21, 2026LANXESS Aktiengesellschaft, Annual General Meeting, May 21, 2026, at 10:00 W. Europe Standard Time.
Reported Earnings • Mar 19Full year 2025 earnings released: €6.68 loss per share (vs €2.05 loss in FY 2024)Full year 2025 results: €6.68 loss per share (further deteriorated from €2.05 loss in FY 2024). Revenue: €5.67b (down 11% from FY 2024). Net loss: €577.0m (loss widened 226% from FY 2024). Revenue is forecast to grow 2.4% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Chemicals industry in Italy. Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has fallen by 32% per year, which means it is performing significantly worse than earnings.
Upcoming Dividend • May 15Upcoming dividend of €0.10 per shareEligible shareholders must have bought the stock before 22 May 2026. Payment date: 27 May 2026. The company is not currently making a profit but it is cash flow positive. Trailing yield: 0.5%. Lower than top quartile of Italian dividend payers (4.4%). Lower than average of industry peers (3.3%).
Reported Earnings • May 07First quarter 2026 earnings released: €1.63 loss per share (vs €0.66 loss in 1Q 2025)First quarter 2026 results: €1.63 loss per share (further deteriorated from €0.66 loss in 1Q 2025). Revenue: €1.38b (down 14% from 1Q 2025). Net loss: €141.0m (loss widened 147% from 1Q 2025). Revenue is forecast to grow 3.7% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has fallen by 21% per year, which means it is performing significantly worse than earnings.
Declared Dividend • Apr 13Dividend of €0.10 announcedDividend of €0.10 is the same as last year. Ex-date: 22nd May 2026 Payment date: 27th May 2026 Dividend yield will be 0.5%, which is lower than the industry average of 2.8%.
お知らせ • Apr 12LANXESS Aktiengesellschaft announces Annual dividend, payable on May 27, 2026LANXESS Aktiengesellschaft announced Annual dividend of EUR 0.1000 per share payable on May 27, 2026, ex-date on May 22, 2026 and record date on May 25, 2026.
お知らせ • Apr 10LANXESS Aktiengesellschaft, Annual General Meeting, May 21, 2026LANXESS Aktiengesellschaft, Annual General Meeting, May 21, 2026, at 10:00 W. Europe Standard Time.
Reported Earnings • Mar 19Full year 2025 earnings released: €6.68 loss per share (vs €2.05 loss in FY 2024)Full year 2025 results: €6.68 loss per share (further deteriorated from €2.05 loss in FY 2024). Revenue: €5.67b (down 11% from FY 2024). Net loss: €577.0m (loss widened 226% from FY 2024). Revenue is forecast to grow 2.4% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Chemicals industry in Italy. Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has fallen by 32% per year, which means it is performing significantly worse than earnings.
New Risk • Mar 08New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Italian stocks, typically moving 8.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (17% operating cash flow to total debt). Share price has been highly volatile over the past 3 months (8.4% average weekly change).
Buy Or Sell Opportunity • Jan 21Now 24% overvaluedOver the last 90 days, the stock has fallen 18% to €17.42. The fair value is estimated to be €14.01, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 11% over the last 3 years. Meanwhile, the company became loss making. For the next 3 years, revenue is forecast to grow by 1.6% per annum. Earnings are also forecast to grow by 56% per annum over the same time period.
Buy Or Sell Opportunity • Dec 29Now 22% overvaluedOver the last 90 days, the stock has fallen 17% to €17.57. The fair value is estimated to be €14.36, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 11% over the last 3 years. Meanwhile, the company became loss making. For the next 3 years, revenue is forecast to grow by 1.5% per annum. Earnings are also forecast to grow by 39% per annum over the same time period.
Buy Or Sell Opportunity • Nov 27Now 22% overvaluedOver the last 90 days, the stock has fallen 29% to €17.30. The fair value is estimated to be €14.12, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 11% over the last 3 years. Meanwhile, the company became loss making. For the next 3 years, revenue is forecast to grow by 1.6% per annum. Earnings are also forecast to grow by 45% per annum over the same time period.
Reported Earnings • Nov 08Third quarter 2025 earnings released: €0.89 loss per share (vs €0.012 profit in 3Q 2024)Third quarter 2025 results: €0.89 loss per share (down from €0.012 profit in 3Q 2024). Revenue: €1.34b (down 16% from 3Q 2024). Net loss: €77.0m (down €78.0m from profit in 3Q 2024). Revenue is forecast to grow 2.0% p.a. on average during the next 3 years, compared to a 7.7% growth forecast for the Chemicals industry in Italy. Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has only fallen by 24% per year, which means it has not declined as severely as earnings.
New Risk • Nov 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 5.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (18% operating cash flow to total debt). Minor Risk Share price has been volatile over the past 3 months (5.9% average weekly change).
Buy Or Sell Opportunity • Nov 04Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 19% to €19.39. The fair value is estimated to be €24.29, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 9.2% over the last 3 years. Meanwhile, the company became loss making. For the next 3 years, revenue is forecast to grow by 1.0% per annum. Earnings are also forecast to grow by 64% per annum over the same time period.
お知らせ • Oct 07+ 3 more updatesLANXESS Aktiengesellschaft to Report Q3, 2026 Results on Nov 05, 2026LANXESS Aktiengesellschaft announced that they will report Q3, 2026 results at 7:00 AM, Central European Standard Time on Nov 05, 2026
New Risk • Sep 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 5.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (18% operating cash flow to total debt). Minor Risk Share price has been volatile over the past 3 months (5.4% average weekly change).
Reported Earnings • Aug 14Second quarter 2025 earnings released: €0.52 loss per share (vs €0.18 loss in 2Q 2024)Second quarter 2025 results: €0.52 loss per share (further deteriorated from €0.18 loss in 2Q 2024). Revenue: €1.47b (down 13% from 2Q 2024). Net loss: €45.0m (loss widened 181% from 2Q 2024). Revenue is forecast to grow 2.4% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Chemicals industry in Italy. Over the last 3 years on average, earnings per share has fallen by 57% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings.
New Risk • Aug 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 5.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.4x net interest cover). Minor Risk Share price has been volatile over the past 3 months (5.4% average weekly change).
New Risk • Jul 04New major risk - Revenue and earnings growthEarnings have declined by 69% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.4x net interest cover). Earnings have declined by 69% per year over the past 5 years.
Upcoming Dividend • May 16Upcoming dividend of €0.10 per shareEligible shareholders must have bought the stock before 23 May 2025. Payment date: 27 May 2025. The company is not currently making a profit but it is cash flow positive. Trailing yield: 0.4%. Lower than top quartile of Italian dividend payers (5.4%). Lower than average of industry peers (2.6%).
Reported Earnings • May 10First quarter 2025 earnings released: €0.66 loss per share (vs €1.14 loss in 1Q 2024)First quarter 2025 results: €0.66 loss per share (improved from €1.14 loss in 1Q 2024). Revenue: €1.60b (flat on 1Q 2024). Net loss: €57.0m (loss narrowed 42% from 1Q 2024). Revenue is forecast to grow 2.0% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Chemicals industry in Italy. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 68 percentage points per year, which is a significant difference in performance.
お知らせ • Apr 11LANXESS Aktiengesellschaft, Annual General Meeting, May 22, 2025LANXESS Aktiengesellschaft, Annual General Meeting, May 22, 2025, at 10:00 W. Europe Standard Time.
お知らせ • Apr 02UBE Corporation (TSE:4208) completed the acquisition of Urethane Systems Business of LANXESS Aktiengesellschaft (XTRA:LXS) for approximately €500 million.UBE Corporation (TSE:4208) signed a contract to acquire Urethane Systems Business of LANXESS Aktiengesellschaft (XTRA:LXS) for an enterprise value of €460 million on October 3, 2024. For the last twelve months period ending September 30, 2024, Urethane Systems Business of LANXESS reported total revenue of €265 million and EBITDA of €50 million. The acquisition price is expected to be confirmed based on the price adjustment indicated in the stock purchase agreement. The acquisition will be financed through cash on hand and interest-bearing debt. The Urethane Systems business comprises 5 manufacturing sites globally as well as application laboratories in the USA, Europe and China. UBE Corporation will take over all operations from LANXESS with a total of around 400 employees. LANXESS will use the proceeds to reduce its net debt. The transaction is subject to the approval of the relevant authorities including regulatory approval. The transaction is expected to close in the first half of 2025. Nomura Holding America, Inc. acted as financial advisor to UBE Corporation. Matthias Töke, Katharina Spenner LL.M., Joachim Fröhlich LL.M., Katharina Weiner, Daniel Bork, Christoph Becker, Ariane Schaaf, Simone (Bach) Rieken LL.M., Johannes M. Baumann, LL.M., Christian Atzler, Christian Vocke, Richard Raoul Stefanink, Patrick H. Wilkening, Markus Hecht, Christian Reichel and Nicolas Kredel LL.M. of Baker & Mckenzie Partnerschaft Von Rechtsanwälten Wirtschaftsprüfern,Steuerberatern Und Solicitors acted as legal advisor to UBE Corporation. Masahiro Inaba, Byron Frost and Tetsuo Tsujimoto of Baker & McKenzie (Gaikokuho Joint Enterprise) acted as legal advisor to UBE Corporation. UBE Corporation (TSE:4208) completed the acquisition of Urethane Systems Business of LANXESS Aktiengesellschaft (XTRA:LXS) for approximately €500 million on April 1, 2025. All relevant antitrust authorities had granted the necessary approvals for the transaction
お知らせ • Oct 04UBE Corporation (TSE:4208) signed a contract to acquire Urethane Systems Business of LANXESS Aktiengesellschaft (XTRA:LXS) for an enterprise value of €460 million.UBE Corporation (TSE:4208) signed a contract to acquire Urethane Systems Business of LANXESS Aktiengesellschaft (XTRA:LXS) for an enterprise value of €460 million on October 3, 2024. For the last twelve months period ending September 30, 2024, Urethane Systems Business of LANXESS reported total revenue of €265 million and EBITDA of €50 million. The acquisition price is expected to be confirmed based on the price adjustment indicated in the stock purchase agreement. The acquisition will be financed through cash on hand and interest-bearing debt. The Urethane Systems business comprises 5 manufacturing sites globally as well as application laboratories in the USA, Europe and China. UBE Corporation will take over all operations from LANXESS with a total of around 400 employees. LANXESS will use the proceeds to reduce its net debt. The transaction is subject to the approval of the relevant authorities including regulatory approval. The transaction is expected to close in the first half of 2025.
